Antiresorptive therapies in osteoporosis
Abstract
Osteoporosis is a systemic skeletal disorder that is characterised by low bone mineral density (BMD) and deterioration of bone tissue. Eventually, this leads to disruption of bone microarchitecture, a compromised bone strength and an increase risk of fracture. Antiresorptive therapies are used to increase bone strength and reduce the risk of fracture in individuals with osteoporosis. The most common antiresorptives are bisphosphonates, estrogens, selective estrogen receptor modulators (SERM) and the human monoclonal antibody against RANKL (Denosumab).
Osteoporose ist eine systemische Skeletterkrankung, die durch eine reduzierte Knochenmasse und eine gestörte Mikroarchitektur des Knochens gekennzeichnet ist. Dies führt zu einer erhöhten Fragilität und Frakturanfälligkeit. Antiresorptive Substanzen hemmen die Aktivität der Osteoklasten und stellen eine wesentliche Säule der medikamentösen Osteoporosetherapie dar. Zu den wichtigsten Vertretern zählen Bisphosphonate, Östrogene im Rahmen einer Hormonersatztherapie (HRT), selektive Östrogenrezeptor-Modulatoren (SERM) und der humane Anti-RANKL-Antikörper Denosumab.
Read the paper
Related studies
- Development of a crushable foam model for human trabecular bone
- Data-driven motion compensation in HR-pQCT.
- Modeling of structure, quality, and function in the orthodontic patient
- Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation
- Effect of fabric on the accuracy of computed tomography-based finite element analyses of the vertebra
- Use of interventions involving virtual reality tasks during the climacteric: a systematic review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.